Abstract:Cancer is a significant health hazard of the 21st century, and GLOBOCAN predicts increasing cancer incidence in the coming decades. Though several conventional treatment modalities exist, most of them end up causing off-target and debilitating effects, and drug resistance acquisition. Advances in our understanding of tumor molecular biology offer alternative strategies for precise, robust, and potentially less toxic treatment paradigms for circumventing the disease at the cellular and molecular level. Several deregulated molecules associated with tumorigenesis have been developed as targets in RNA interference (RNAi) based cancer therapeutics. RNAi, a post-transcriptional gene regulation mechanism, has significantly gained attention because of its precise multi-targeted gene silencing. Although the RNAi approach is favorable, the direct administration of small oligonucleotides has not been fruitful because of their inherent lower half-lives and instability in the biological systems. Moreover, the lack of an appropriate delivery system to the primary site of the tumor that helps determine the potency of the drug and its reach, has limited the effective medical utilization of these bio-drugs. Nanotechnology, with its unique characteristics of enhanced permeation and better tumor-targeting efficiency, offers promising solutions owing to the various possibilities and amenability for modifications of the nanoparticles to augment cancer therapeutics. Nanoparticles could be made multimodal, by designing and synthesizing multiple desired functionalities, often resulting in unique and potentially applicable biological structures. A small number of Phase I clinical trials with systemically administered siRNA molecules conjugated with nanoparticles have been completed and the results are promising, indicating that, these new combinatorial therapies can successfully and safely be used to inhibit target genes in cancer patients to alleviate some of the disease burden. In this review, we highlight different types of nano-based delivery strategies for engineering Nano-RNAi-based bio drugs. Furthermore, we have highlighted the insights gained from current research that are entering the preclinical evaluation and information about initial clinical developments, shaping the future for next generation cancer therapeutics.

RNA Oncological Therapeutics: Intracellular Hairpin RNA Assembly Enables MicroRNA-Triggered Anticancer Functionality

RNA interference mediated by oncolytic viruses in tumor therapy

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

RNA Interference-Based Cancer Drugs: The Roadblocks, and the "Delivery" of the Promise

RNA-Based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment

RNA-based Therapeutics: an Overview and Prospectus

Emerging Progress of RNA-Based Antitumor Therapeutics

RNA interference and tumor gene therapy

RNA therapeutics in cancer treatment

Therapeutic applications of RNA nanostructures

Small interfering RNA for experimental cancer therapy.

Recent Advances in RNA-Targeted Cancer Therapy

RNA origami as a vaccine assembly platform to promote CD8 T Cell mediated anti-tumor immunity

RNA Interference and Nanotechnology: A Promising Alliance for Next Generation Cancer Therapeutics

In Vitro Studies of Polyethyleneimine Coated Mirna Microspheres As Anticancer Agents

Nano-based delivery of RNAi in cancer therapy

Non-Coding RNA in Tumor Cells and Tumor-Associated Myeloid Cells-Function and Therapeutic Potential

RNA nanostructures for targeted drug delivery and imaging

RNA 4WJ for spontaneous cancer-targeting, effective tumor-regression, metastasis suppression, fast renal excretion and undetectable toxicity

Tumor-Targeted Anti-VEGF RNAi Capable of Sequentially Responding to Intracellular Microenvironments for Potent Systemic Tumor Suppression.

Antitumoral RNA‐targeted oligonucleotide therapeutics: the third pillar after small molecule inhibitors and antibodies